Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)

被引：5

作者：

Kim, Young ^{[1
]}

Hida, Toyoaki ^{[2
]}

Nokihara, Hiroshi ^{[3
]}

Kondo, Masashi ^{[4
]}

Azuma, Koichi ^{[5
]}

Seto, Takashi ^{[6
]}

Takiguchi, Yuichi ^{[7
]}

Nishio, Makoto ^{[8
]}

Yoshioka, Hiroshige ^{[9
]}

Imamura, Fumio ^{[10
]}

Hotta, Katsuyuki ^{[11
]}

Watanabe, Satoshi ^{[12
]}

Goto, Koichi ^{[13
]}

Nakagawa, Kazuhiko ^{[14
]}

Mitsudomi, Tetsuya ^{[15
]}

Yamamoto, Nobuyuki ^{[16
]}

Kuriki, Hiroshi ^{[17
]}

Asabe, Ryoichi ^{[17
]}

Tanaka, Tomohiro ^{[18
]}

Tamura, Tomohide ^{[19
]}

机构：

[1] Kyoto Univ, Kyoto, Japan

[2] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[3] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[4] Nagoya Univ, Resp Med, Nagoya, Aichi, Japan

[5] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan

[6] Natl Kyushu Canc Ctr, Fukuoka, Japan

[7] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chiba, Japan

[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[9] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan

[10] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan

[11] Okayama Univ Hosp, Okayama, Japan

[12] Osaka Med Ctr Canc & Cardiovasc Dis, Niigata, Japan

[13] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Chiba, Japan

[14] Kindai Univ, Fac Med, Osaka, Japan

[15] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan

[16] Wakayama Med Univ, Internal Med, Wakayama, Japan

[17] Chugai Pharmaceut Co Ltd, Tokyo, Japan

[18] Chugai Pharmaceut Co Ltd, Clin Sci & Strategy Dept, Tokyo, Japan

[19] St LukeS Int Hosp, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK Inhibitor; ALK plus NSCLC;

D O I：

10.1016/j.jtho.2016.11.427

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.03

引用

页码：S378 / S379

页数：2

共 50 条

[1] Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC): Primary results from the J-ALEX study.
Nokihara, Hiroshi
Hida, Toyoaki
Kondo, Masashi
Kim, Young Hak
Azuma, Koichi
Seto, Takashi
Takiguchi, Yuichi
Jo, Makoto Nish
Yoshioka, Hiroshige
Imamura, Fumio
Hotta, Katsuyuki
Watanabe, Satoshi
Goto, Koichi
Nakagawa, Kazuhiko
Mitsudomi, Tetsuya
Yamamoto, Nobuyuki
Kuriki, Hiroshi
Asabe, Ryoichi
Tanaka, Tomohiro
Tamura, Tomohide
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC).
Yoshioka, Hiroshige
Hida, Toyoaki
Nokihara, Hiroshi
Morise, Masahiro
Kim, Young Hak
Azuma, Koichi
Seto, Takashi
Takiguchi, Yuichi
Nishio, Makoto
Kumagai, Toru
Hotta, Katsuyuki
Watanabe, Satoshi
Goto, Koichi
Satouchi, Miyako
Kozuki, Toshiyuki
Nakagawa, Kazuhiko
Mitsudomi, Tetsuya
Yamamoto, Nobuyuki
Yoshimoto, Takuya
Tamura, Tomohide
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer
Gainor, Justin F.
Shaw, Alice T.
LANCET, 2017, 390 (10089): : 3 - 4
[4] Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC).
Seto, Takashi
Nishio, Makoto
Hida, Toyoaki
Nokihara, Hiroshi
Morise, Masahiro
Kim, Young Hak
Azuma, Koichi
Takiguchi, Yuichi
Yoshioka, Hiroshige
Kumagai, Toru
Hotta, Katsuyuki
Watanabe, Satoshi
Goto, Koichi
Satouchi, Miyako
Kozuki, Toshiyuki
Nakagawa, Kazuhiko
Mitsudomi, Tetsuya
Yamamoto, Nobuyuki
Asakawa, Takashi
Tamura, Tomohide
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naive ALK fusion positive non-small cell lung cancer (ALK plus NSCLC).
Takiguchi, Yuichi
Hida, Toyoaki
Nokihara, Hiroshi
Kondo, Masashi
Kim, Young Hak
Azuma, Koichi
Seto, Takashi
Nishio, Makoto
Yoshioka, Hiroshige
Imamura, Fumio
Hotta, Katsuyuki
Watanabe, Satoshi
Goto, Koichi
Nakagawa, Kazuhiko
Mitsudomi, Tetsuya
Yamamoto, Nobuyuki
Kuriki, Hiroshi
Inagaki, Naohito
Tanaka, Tomohiro
Tamura, Tomohide
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[6] Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study
Shaw, Alice Tsang
Peters, Solange
Mok, Tony
Gadgeel, Shirish M.
Ahn, Jin Seok
Ou, Sai-Hong Ignatius
Pero, Maurice
Dziadziuszko, Rafal
Kim, Dong-Wan
Rosell, Rafael
Zeaiter, Ali Hassan
Liu, Ting
Golding, Sophie
Balas, Bogdana
Noe, Johannes
Morcos, Peter N.
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7] Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
Shaw, Alice Tsang
Peters, Solange
Mok, Tony
Gadgeel, Shirish M.
Ahn, Jin Seok
Ou, Sai-Hong Ignatius
Perol, Maurice
Dziadziuszko, Rafal
Kim, Dong-Wan
Rosell, Rafael
Zeaiter, Ali Hassan
Liu, Ting
Golding, Sophie
Balas, Bogdana
Noé, Johannes
Morcos, Peter N.
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
[8] Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Nakagawa, Kazuhiko
Hida, Toyoaki
Nokihara, Hiroshi
Morise, Masahiro
Azuma, Koichi
Kim, Young Hak
Seto, Takashi
Takiguchi, Yuichi
Nishio, Makoto
Yoshioka, Hiroshige
Kumagai, Toru
Hotta, Katsuyuki
Watanabe, Satoshi
Goto, Koichi
Satouchi, Miyako
Kozuki, Toshiyuki
Koyama, Ryo
Mitsudomi, Tetsuya
Yamamoto, Nobuyuki
Asakawa, Takashi
Hayashi, Morihiko
Hasegawa, Wakako
Tamura, Tomohide
LUNG CANCER, 2020, 139 : 195 - 199
[9] Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Nishio, Makoto
Nakagawa, Kazuhiko
Mitsudomi, Tetsuya
Yamamoto, Nobuyuki
Tanaka, Tomohiro
Kuriki, Hiroshi
Zeaiter, Ali
Tamura, Tomohide
LUNG CANCER, 2018, 121 : 37 - 40
[10] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, Toyoaki
Nokihara, Hiroshi
Kondo, Masashi
Kim, Young Hak
Azuma, Koichi
Seto, Takashi
Takiguchi, Yuichi
Nishio, Makoto
Yoshioka, Hiroshige
Imamura, Fumio
Hotta, Katsuyuki
Watanabe, Satoshi
Goto, Koichi
Satouchi, Miyako
Kozuki, Toshiyuki
Shukuya, Takehito
Nakagawa, Kazuhiko
Mitsudomi, Tetsuya
Yamamoto, Nobuyuki
Asakawa, Takashi
Asabe, Ryoichi
Tanaka, Tomohiro
Tamura, Tomohide
LANCET, 2017, 390 (10089): : 29 - 39

← 1 2 3 4 5 →